Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Albireo, a Swedish biotechnology company focusing on the development of therapeutics for gastrointestinal diseases, has appointed Hans Graffner, as chief medical officer.
Subscribe to our email newsletter
Dr Graffner will oversee the clinical development programs at Albireo with initial focus on the lead program A3309, a therapeutic with a novel mechanism of action targeting the treatment of patients with chronic constipation.
Most recently, Dr Graffner was the senior medical director at Merck Serono, leading clinical development of products mainly in the areas of autoimmune diseases, including inflammatory bowel diseases.